Literature DB >> 2983753

Iron(III)-adriamycin and Iron(III)-daunorubicin complexes: physicochemical characteristics, interaction with DNA, and antitumor activity.

H Beraldo, A Garnier-Suillerot, L Tosi, F Lavelle.   

Abstract

Fe(III) complexes of two anthracyclines, adriamycin and daunorubicin, have been studied. Using potentiometric and spectroscopic measurements, we have shown that adriamycin and daunorubicin form two well-defined species with Fe(III), which can be formulated as respectively Fe(HAd)3 and Fe(HDr)3. In these formulas, HAd and HDr stand for adriamycin and daunorubicin in which the 1,4-dihydroxy-anthraquinone moiety is half-deprotonated. Both complexes are six-membered chelates. The stability constant is beta = (2.5 +/- 0.5) X 10(28) for both complexes. Interaction with DNA has been studied showing that, despite strong coordination to Fe(III), anthracyclines are able to intercalate between DNA bases pairs, releasing the metal. These complexes display antitumor activity against P 388 leukemia that compares with that of the free drug. Fe(HAd)3, unlike adriamycin, does not catalyze the flow of electrons from NADH to molecular oxygen through NADH dehydrogenase. Moreover, it is shown that the triferric adriamycin compound so called "quelamycin" is in fact a mixture of Fe(HAd)3 and polymeric ferric hydroxide.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983753     DOI: 10.1021/bi00323a007

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  The interaction of Fe(III), adriamycin and daunomycin with nucleotides and DNA and their effects on cell growth of fibroblasts (NIH-3T3).

Authors:  I Di Liegro; A Cestelli; B F Matzanke; E Bill; A X Trautwein
Journal:  Biometals       Date:  1996-04       Impact factor: 2.949

2.  Nucleosomal histone protein protects DNA from iron-mediated damage.

Authors:  H U Enright; W J Miller; R P Hebbel
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

3.  Nanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells.

Authors:  Hans C Arora; Mark P Jensen; Ye Yuan; Aiguo Wu; Stefan Vogt; Tatjana Paunesku; Gayle E Woloschak
Journal:  Cancer Res       Date:  2011-12-12       Impact factor: 12.701

4.  Cardiotoxicity and antitumor activity of a copper(II)-doxorubicin chelate.

Authors:  E Monti; L Paracchini; F Piccinini; V Malatesta; F Morazzoni; R Supino
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).

Authors:  B B Hasinoff
Journal:  Agents Actions       Date:  1990-03

6.  Study on the interaction of an anthracycline disaccharide with DNA by spectroscopic techniques and molecular modeling.

Authors:  Yan Lu; Gong-Ke Wang; Juan Lv; Gui-Sheng Zhang; Qing-Feng Liu
Journal:  J Fluoresc       Date:  2010-10-16       Impact factor: 2.217

7.  The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.

Authors:  B B Hasinoff
Journal:  Agents Actions       Date:  1989-03

Review 8.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

9.  The iron(III)-adriamycin complex inhibits cytochrome c oxidase before its inactivation.

Authors:  B B Hasinoff; J P Davey
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

10.  Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.

Authors:  B C Hüsken; J de Jong; B Beekman; R C Onderwater; W J van der Vijgh; A Bast
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.